• Mashup Score: 2
    Predicting Recurrence in Colorectal Cancer Using Postoperative Circulating Tumor DNA Dynamics - The ASCO Post - 7 month(s) ago

    Postoperative molecular residual disease detected by circulating tumor DNA (ctDNA) at 4 weeks after resection has emerged as the strongest prognostic risk factor for disease-free survival in patients with resected colorectal cancer. This finding was observed regardless of BRAF V600E status and microsatellite instability–high (MSI-H) status, according to an update of the observational GALAXY study presented at the 2023 ASCO Breakthrough meeting. 1 BRAF status and MSI-H status were also found to be significa

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Predicting Recurrence in Colorectal Cancer Using Postoperative Circulating Tumor DNA Dynamics https://t.co/nVRPNvFqNH #crcsm #colorectalcancer #oncology #ASCOBT23

  • Mashup Score: 0
    Study Shows Exercise May Improve Sexual Function in Men With Prostate Cancer - The ASCO Post - 7 month(s) ago

    It seems that exercise is good for almost everything, including prostate cancer. In fact, exercise had a positive effect on sexual function and enjoyment in men with prostate cancer, according to a recent study presented at the 2023 ASCO Breakthrough meeting by lead study author Daniel Galvão, PhD, of the Exercise Medicine Research Institute at Edith Cowan University, Perth, Australia. 1 The study showed that exercise, in the form of supervised resistance and aerobic exercises, improved erectile function

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Study Shows Exercise May Improve Sexual Function in Men With Prostate Cancer https://t.co/T8oflwRvQg #pcsm #ASCOBT23 #prostatecancer

  • Mashup Score: 2
    Rising After Struggle: Surviving My First ASCO Breakthrough in Japan - The ASCO Post - 7 month(s) ago

    After a year of hard work preparing a strong abstract for the prestigious 2023 ASCO Annual Meeting, I finally received an acceptance letter from the scientific committee. I was overjoyed to see the efforts of our multinational team being rewarded. A few moments later, I received the decision regarding the 2023 Conquer Cancer Merit Award from the Scientific Program Committee; our work was not selected! My joy quickly vanished as I realized that presenting a paper at this meeting would demand a substantial

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Rising After Struggle: Surviving My First ASCO Breakthrough in Japan, by Khalid El Bairi, MD https://t.co/420FtHGJ95 @elbairikhalid19 #ASCOBT23

  • Mashup Score: 3
    Aki Morikawa, MD, PhD, on Brain Metastases: New Findings on Predictive Drug Testing - The ASCO Post - 7 month(s) ago

    Aki Morikawa, MD, PhD, of the University of Michigan, and her team explored the use of patient-derived organoids from breast cancer brain metastases to evaluate drug sensitivities in a clinically meaningful time frame. Along with molecular profiling, she says, this method may further personaliz e therapy and possibly lead to novel treatment options for this population. Wei Wu, MD, PhD, of the University of California, San Francisco, discusses new findings that suggest his team’s deep learning neural

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Aki Morikawa, MD, PhD, on Brain Metastases: New Findings on Predictive Drug Testing https://t.co/gWaunn2o9W #bcsm #breastcancer #oncology #ASCOBT23 @UMRogelCancer

  • Mashup Score: 0
    Postoperative ctDNA Provides Prognostic Value for DFS Outcomes in CRC - 8 month(s) ago

    Circulating tumor DNA status at the time of postoperative minimal residual disease assessment was found to be a prognostic factor for disease-free survival in patients with radically resected stage II to IV colorectal cancer.

    Source: www.onclive.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      According to updated data from the observational GALAXY study, patients with CRC and negative postoperative ctDNA at 4 weeks experienced an 18-month DFS rate of 93.9% vs 51.6% in patients with positive ctDNA. @ASCO #ASCOBT23 #crcsm https://t.co/z3CFcA35Vn https://t.co/gZiAFkR40k

  • Mashup Score: 0
    Updates on Cancer Therapies Under Study From 2023 ASCO Breakthrough - The ASCO Post - 8 month(s) ago

    Presented here are some brief summaries of novel therapies under study from the 2023 ASCO Breakthrough meeting in Yokohama, Japan. The subjects range from new observations about a HER2-directed bispecific antibody and systemic treatment of gastric cancer to an option for treating hand-foot syndrome in patients on capecitabine. In addition, dexamethasone premedication may reduce the immunogenicity of COVID-19 vaccinations in patients with solid tumors of any type, another study suggests. First-line

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Updates on Cancer Therapies Under Study From 2023 ASCO Breakthrough https://t.co/E3wR7Bld8O #cancer #oncology #ASCOBT23

Load More